From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy

Anti-Cancer Agents in Medicinal Chemistry, 6(4): 287-301.

Author(s): Barbara Gatto and Marco Cavalli.

Affiliation: Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy.


Cancer cells, by releasing pro-angiogenic factors, stimulate the growth of the thick capillary net necessary for the nourishment of the tumor mass. The battle to defeat cancer uses today different approaches based on the inhibition of pathological angiogenesis: several compounds, either synthetic or biotech, aimed at this complex process, are under development. Vascular endothelial growth factor (VEGF) is considered the main target for an anti-cancer therapy based on angiogenesis inhibition; the goal is to block the interaction between this cytokine and its receptors in order to stop the intracellular signaling pathways leading to endothelium remodeling. FDA recently approved two drugs specifically aimed at VEGF, bevacizumab, a humanized monoclonal antibody, and pegaptinib, a pegylated aptamer with application in ophthalmic pathologies. These two approvals validate anti-VEGF therapy for clinical use, and show how biotech companies are investing on angiogenesis using different approaches, i.e. exploiting protein drugs and oligonucleotide-based therapeutics. Monoclonal antibodies, as well as other high molecular weight products like cytokine-traps, aptamers and short interfering RNA (siRNA), are designed to target VEGF and its receptors. Their design, production and clinical advancement in cancer and other pathological conditions linked to angiogenesis will be specifically addressed in this review.


Angiogenesis, VEGF, MAbs, Aptamers, VEGF-Trap, bevacizumab, ranibizumab, pegaptinib.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 4
First Page: 287
Last Page: 301
Page Count: 15
DOI: 10.2174/187152006777698178
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science